Long term clinical results of autologous CD133+ bone marrow cells transplantation in ST elevation myocardial infarction patients
Aim. To study the long-term effectiveness and safety of CD133+ bone marrow cells transplantation in ST elevation myocardial infarction (STEMI) patients. Material and methods. To the open-label, randomized study we included 26 patients, admitted with primary MI during years 2006-2007 to SRI of Cardiology. Patients were randomized to two groups: 1st - stenting of infarction-related coronary artery (IRA) and transplantation of CD133 bone marrow cells (n=10), 2nd - only stenting of IRA (n=16). Baseline clinical and anamnestic parameters were similar. In 7,70±0,42 years after MI we performed control investigation, that included physical examination, 6-minute walking test (6WT), echocardiography. Results. It is found, that in the 1st group comparing to the 2nd, total and cardiovasular mortality was lower (20% (2) vs 44% (7), p=0,11; 22% (2) vs 25% (4), p=0,58, resp.). In the 2nd there were 7 cases of recurrent MI (44% of patients), 4 of those were fatal, but in the 1st group there were no any recurrent MI (p=0,01). During the whole follow-up, unstable angina was more common in the 2nd group (11 (69%) vs 2 (20%) in 1st, р=0,04). CHF of II FC and higher was more common in 2nd group: 8 (50%) vs 2 (20%) in 1st, р=0,07. Also, there were significant differences in analysis of volumetrics of the left ventricle (EDV - 100,7±50,2 mL vs 144,4±42,7 mL, р=0,049; ESV - 56,3±37,8 mL vs 89,7±38,7 mL, р=0,049, resp.). These values were lower in the 1st group. Conclusion. The results demonstrated that transplantation of autologous CD133+ bone marrow cells positively influences long-term survival of patients, CHD course and volumetric LV parameters.